Betta Pharmaceuticals Co., Ltd.

Jacobio Pharmaceuticals Co., Ltd.

Jinlong Bai

Wei Long

Shaojing Hu

Xiangyong Liu

Cunbo Ma

Panliang Gao

Di Kang

Xinping Wu

Xiaoyan Pei

Jie Chu

Chunwei Wen

Provided are certain novel pyrazine derivatives (I) as SHP2 inhibitors which is shown as formula (I), their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided are fused heterocyclic derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder. 

Heterocyclic ring derivatives useful as SHP2 inhibitors

Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative, and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.

Protein tyrosine kinase modulators and methods of use

Growing community of inventors

Beijing, China

Jinlong Bai